Alpha-Glucosidase Inhibitors in Aging and Aging-Related Diseases: Clinical Applications and Relevant Mechanisms

Ling Zhong1, Jielin Yang2, Jibran Nehal Syed2

  • 1Department of Endocrinology and Metabolism, Department of Biotherapy, Laboratory of Diabetes and Metabolism Research, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.

Aging and Disease
|January 3, 2025
PubMed

Insights

Alpha-glucosidase inhibitors (AGIs) show promise in delaying aging and treating age-related diseases. These antidiabetic drugs modulate key pathways, offering potential healthspan benefits beyond diabetes management.

Area of Science:

  • Gerontology
  • Pharmacology

Background:

  • Aging is a universal process involving cellular decline, increasing susceptibility to diseases like diabetes, cardiovascular conditions, and cancer.
  • Interventions that delay aging can mitigate these conditions and improve overall health.
  • Alpha-glucosidase inhibitors (AGIs) are established antidiabetic drugs that manage hyperglycemia by inhibiting carbohydrate digestion.

Purpose of the Study:

  • To review recent advancements in using alpha-glucosidase inhibitors (AGIs) for aging and age-related disease prevention and treatment.
  • To explore the mechanisms through which AGIs impact aging processes.

Main Methods:

  • Literature review of studies on AGIs and aging.
  • Analysis of AGIs' effects on oxidative stress, gut microbiota, inflammation, and nutrient-sensing pathways.

Main Results:

  • AGIs demonstrate potential in extending lifespan and treating aging-related diseases.
  • Mechanisms include modulation of oxidative stress, gut microbiota, inflammatory responses, and nutrient-sensing pathways.
  • AGIs offer benefits beyond their antidiabetic effects.

Conclusions:

  • Alpha-glucosidase inhibitors represent a promising therapeutic strategy for combating aging and associated diseases.
  • Further research into AGIs' anti-aging properties could lead to novel interventions for promoting healthspan.

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
132
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
108
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
104
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
249
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
117
Aging01:26

Aging

Aging is a complex biological phenomenon influenced by various processes that affect cellular and systemic functions. Several prominent theories attempt to explain its mechanisms, highlighting cellular limitations, oxidative damage, and hormonal changes as central factors in aging.
Cellular Clock Theory
The cellular clock theory posits that the human lifespan is closely tied to the finite capacity of cells to divide, a phenomenon governed by telomeres, which are protective caps at the ends of...
19